A new asthma combined maintenance and reliever treatment has been launched in the UK.
The inhaler, being marketed as Fostair MART, combines beclometasone and formoterol.
Its manufacturer Chiesi Limited said the inhaler was the UK’s first combination asthma treatment that could treat both the small and large airways of the lung.
This was because it contains extra-fine particles of the active medicine that are around half the size of those found in other combination inhalers, the company said in a statement announcing the launch.
It is also the first time a MART combination has become available in a pressurised Metered Dose Inhaler (pMDI) – the most commonly used type of inhaler device in the UK.
The launch was timed to coincide with World Asthma Day on 7 May.
Are you able to Speak Out Safely? Sign our petition to put pressure on your trust to support an open and transparent NHS.